Literature DB >> 6281475

Use of fluoresceinated Epstein-Barr virus to study Epstein-Barr virus-lymphoid cell interactions.

R Khelifa, J Menezes.   

Abstract

As a direct approach to visualize Epstein-Barr virus (EBV) binding to its cellular receptors and to learn more on the nature of this binding, virus preparations were conjugated to fluorescein isothiocyanate and used to detect EBV receptors on lymphoid cells. Different enzymatic and chemical treatments were also applied either to the virus or to target cells or to both, and the effect of these treatments on virus binding was then examined. The results obtained show that: (i) EBV can be fluoresceinated without affecting its infectivity or cell binding ability, and the fluoresceinated virus represents an important tool to investigate the biology and nature of EBV interactions with its cellular receptors; (ii) the two virus strains (P3HR-1 and B95-8) share common receptors on Raji cells; (iii) protease treatment of EBV or target cells abrogates virus binding; (iv) EBV receptors regenerate after removal of the protease, and this regeneration is inhibited by cycloheximide or sucrose; (v) EBV particles bear concanavalin A receptors, and this lectin hinders the interaction of the virus with its cellular receptors; (vi) neuraminidase treatment, various monosaccharides, ovalbumin, and glycopeptides derived from EBV or cell surface do not inhibit virus binding. Taken together, the above data also demonstrate that some cellular and viral surface (glyco-) proteins are required for EBV binding to its targets.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6281475      PMCID: PMC256794     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  25 in total

1.  Epstein-Barr virus binding sites on lymphocyte subpopulations and the origin of lymphoblasts in cultured lymphoic cell lines and in the blood of patients with infectious mononucleosis.

Authors:  M F Greaves; G Brown
Journal:  Clin Immunol Immunopathol       Date:  1975-03

2.  Modes of Epstein-Barr virus infection in human floating cell lines.

Authors:  T Sairenji; Y Hinuma
Journal:  Gan       Date:  1973-12

3.  Cloning of immunoglobulin-producing human leukemic and lymphoma cells in long-term cultures.

Authors:  Y Hinuma; J T Grace
Journal:  Proc Soc Exp Biol Med       Date:  1967-01

4.  Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lymphoblastoid cell lines to superinfection with EB-virus.

Authors:  G Klein; L Dombos; B Gothoskar
Journal:  Int J Cancer       Date:  1972-07-15       Impact factor: 7.396

5.  Surface IgM-kappa specificity on a Burkitt lymphoma cell in vivo and in derived culture lines.

Authors:  E Klein; G Klein; J S Nadkarni; J J Nadkarni; H Wigzell; P Clifford
Journal:  Cancer Res       Date:  1968-07       Impact factor: 12.701

6.  Cytotoxicity of a factor isolated from human spleen.

Authors:  C B Lozzio; B B Lozzio
Journal:  J Natl Cancer Inst       Date:  1973-02       Impact factor: 13.506

7.  Some biophysical aspects of E-B virus adsorption to the surfaces of three types of mammalian cells.

Authors:  L Weiss; J S Horoszewicz
Journal:  Int J Cancer       Date:  1971-01-15       Impact factor: 7.396

8.  Release of infectious Epstein-Barr virus by transformed marmoset leukocytes.

Authors:  G Miller; M Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1973-01       Impact factor: 11.205

9.  Glycoproteins of Sindbis virus: priliminary characterization of the oligosaccharides.

Authors:  B M Sefton; K Keegstra
Journal:  J Virol       Date:  1974-09       Impact factor: 5.103

10.  Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes.

Authors:  M Jondal; G Klein
Journal:  J Exp Med       Date:  1973-12-01       Impact factor: 14.307

View more
  9 in total

1.  Detection of individual fluorescently labeled reovirions in living cells.

Authors:  A Georgi; C Mottola-Hartshorn; A Warner; B Fields; L B Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

2.  Topological and operational delineation of antigenic sites on the HN glycoprotein of Newcastle disease virus and their structural requirements.

Authors:  K Nishikawa; T Morishima; T Toyoda; T Miyadai; T Yokochi; T Yoshida; Y Nagai
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

3.  Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2.

Authors:  J D Fingeroth; J J Weis; T F Tedder; J L Strominger; P A Biro; D T Fearon
Journal:  Proc Natl Acad Sci U S A       Date:  1984-07       Impact factor: 11.205

4.  Characterization of a porcine kidney cell line resistant to influenza virus infection.

Authors:  Y Kimura; T Yokochi; T Miyadai; K Yoshida; J Yokoo; K Matsumoto
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

5.  Sendai virus envelopes can mediate Epstein-Barr virus binding to and penetration into Epstein-Barr virus receptor-negative cells.

Authors:  R Khélifa; J Menezes
Journal:  J Virol       Date:  1983-04       Impact factor: 5.103

6.  Biological roles of the major capsid proteins and relationships between the two existing serotypes of infectious bursal disease virus.

Authors:  S K Reddy; A Silim; M J Ratcliffe
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

7.  Model for studying virus attachment: identification and quantitation of Epstein-Barr virus-binding cells by using biotinylated virus in flow cytometry.

Authors:  G Inghirami; M Nakamura; J E Balow; A L Notkins; P Casali
Journal:  J Virol       Date:  1988-07       Impact factor: 5.103

Review 8.  Fluorosomes: fluorescent virus-like nanoparticles that represent a convenient tool to visualize receptor-ligand interactions.

Authors:  Daniela Wojta-Stremayr; Winfried F Pickl
Journal:  Sensors (Basel)       Date:  2013-07-08       Impact factor: 3.576

9.  Neuropilin 1 is an entry factor that promotes EBV infection of nasopharyngeal epithelial cells.

Authors:  Hong-Bo Wang; Hua Zhang; Jing-Ping Zhang; Yan Li; Bo Zhao; Guo-Kai Feng; Yong Du; Dan Xiong; Qian Zhong; Wan-Li Liu; Huamao Du; Man-Zhi Li; Wen-Lin Huang; Sai Wah Tsao; Lindsey Hutt-Fletcher; Yi-Xin Zeng; Elliott Kieff; Mu-Sheng Zeng
Journal:  Nat Commun       Date:  2015-02-11       Impact factor: 14.919

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.